nanobiotix

Nanomedicine company Nanobiotix elects former Aventis vice chairman and CFO Patrick Langlois as its chairman.

PARIS, May 12, 2008-Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced today that it has elected Patrick Langlois as chairman of its non-executive board, effective immediately. Since March 1, 2005, Mr. Langlois has served as a General Partner with PJL CONSEILS, a consulting firm specializing in strategy, corporate development, and M&A activities for healthcare companies. Prior to PJL, he was vice chairman of the management board and chief financial officer at Aventis (created by the merger of Rhône- Poulenc and Hoechst) from May 2002 to September 2004, and executive vice president and chief financial officer of Aventis from December 1999 to May 2002. At Aventis , Mr. Langlois was responsible for finance, corporate
development, and supervision of the company’s dermatology, protein therapeutics, and animal health businesses. Earlier in his career, he was employed by Rhône-Poulenc Group from 1975 to 1999, most recently as chief financial officer and member of the executive committee. In addition to Nanobiotix, Mr. Langlois also is a board member of Shire Pharmaceuticals (UK), Scynexis (USA), and Exonhit Therapeutics (France). In addition, Mr. Langlois has served as a senior advisor to JP Morgan Healthcare since December 2006.

“The addition of such an accomplished industry veteran as Patrick Langlois bears strong testimony to the significant opportunity ahead of Nanobiotix,” said Laurent Levy, Ph.D., chief executive officer of Nanobiotix. “We look forward to reaping the benefits of Patrick’s considerable talent and abundant experience related to accessing the capital markets and building strong strategic partnerships.” “The Company’s NanoXray platform has the potential to be a dramatic innovation in cancer therapy, based on a technology that is designed to allow destruction of cancer cells only,” added Patrick Langlois. “I am very proud to be part of this important mission.”